4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

Heart Failure (HF) is a multi-faceted and life-threatening syndrome characterized by
significant morbidity and mortality, poor functional capacity and quality of life, and high costs …

Background Whether acetazolamide, a carbonic anhydrase inhibitor that reduces proximal
tubular sodium reabsorption, can improve the efficiency of loop diuretics, potentially leading …

Aims The complementary studies FIDELIO-DKD and FIGARO-DKD in patients with type 2
diabetes and chronic kidney disease (CKD) examined cardiovascular and kidney outcomes …

Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

The perception that intracellular lipolysis is a straightforward process that releases fatty
acids from fat stores in adipose tissue to generate energy has experienced major revisions …